(Yicai Global) July 2 -- China's LinkDoc Technology, a medical data company invested by Alibaba Group Holding's healthcare arm, aims to raise up to USD243 million in its initial public offering on the Nasdaq.

The oncology data platform will issue 10.8 million American depositary shares at a price range of USD17.50 to USD19.50, the Beijing-based firm said in its updated prospectus filed with the US Securities and Exchange Commission yesterday. Underwriters may subscribe to an additional 1.6 million ADSs under a greenshoe option.

Six investors, including Alibaba Health Hong Kong Technology, have expressed their intentions to buy nearly half of the shares before the IPO, the prospectus added. The group includes Lake Bleu Capital, Temasek Holdings, UBS Asset Management, Hudson Bay Capital, and Sage Capital. Alibaba's affiliate would spend USD25 million.

Founded in 2014, LinkDoc offers its diagnostics and treatment information services to cancer patients in China via its online and offline platforms. It had set up 34 service centers in 28 provinces with more than 400,000 registered patients by March.

The startup has completed five rounds of financing. The latest one was in March, participated by the Hangzhou-based e-commerce giant. Alibaba currently is the fifth-largest shareholder with its 8.4 percent stake in the IPO-hopeful. But founder and Chief Executive Zhang Tianze has 19.7 percent of the equity, resulting in the biggest stake.

The company is not in the black yet. In 2020, LinkDoc widened its net loss by 12 percent to CNY489 million (USD75.4 million) from 2019 due to its high research and development, as well as labor costs. Its revenue surged 89 percent to CNY942 million.

Editor: Emmi Laine, Xiao Yi